Other
Short-term borrowings/(repayments) less than 90 days — net
Pfizer Short-term borrowings/(repayments) less than 90 days — net increased by 75.4% to -$127.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 67.1%, from -$386.00M to -$127.00M. Over 2 years (FY 2021 to FY 2023), Short-term borrowings/(repayments) less than 90 days — net shows an upward trend with a 492.0% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
Frequent reliance on short-term debt can indicate working capital pressure or seasonal liquidity needs.
Detailed definition
Net cash flow from the issuance and repayment of short-term debt obligations with maturities of less than 90 days. This...
Peer comparison
Commonly reported in the financing section of the cash flow statement.
Metric ID:
other_proceeds_from_repayments_of_short_term_debt_maturi_4fe215Historical Data
16 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$474.00M | $764.00M | -$361.00M | -$220.00M | $599.00M | $491.00M | -$1.09B | $226.00M | $0.00 | -$128.00M | $3.27B | -$2.04B | -$1.49B | -$386.00M | -$517.00M | -$127.00M |
| QoQ Change | — | +261.2% | -147.3% | +39.1% | +372.3% | -18.0% | -322.4% | +120.7% | -100.0% | — | >999% | -162.4% | +27.0% | +74.1% | -33.9% | +75.4% |
| YoY Change | — | — | — | — | +226.4% | -35.7% | -202.5% | +202.7% | -100.0% | -126.1% | +399.2% | <-999% | <-999% | +81.1% | — | +67.1% |
Range-$2.04B – $3.27B
CAGR-29.6%
Avg YoY Growth-141.2%
Median YoY Growth-35.7%
Short-term borrowings/(repayments) less than 90 days — net at Other Companies
Frequently Asked Questions
- What is Pfizer's short-term borrowings/(repayments) less than 90 days — net?
- Pfizer (PFE) reported short-term borrowings/(repayments) less than 90 days — net of -$127.00M in Q1 2026.
- How has Pfizer's short-term borrowings/(repayments) less than 90 days — net changed year-over-year?
- Pfizer's short-term borrowings/(repayments) less than 90 days — net increased by 67.1% year-over-year, from -$386.00M to -$127.00M.
- What is the long-term trend for Pfizer's short-term borrowings/(repayments) less than 90 days — net?
- Over 2 years (2021 to 2023), Pfizer's short-term borrowings/(repayments) less than 90 days — net has grown at a 492.0% compound annual growth rate (CAGR), from -$96.00M to $3.37B.
- What does short-term borrowings/(repayments) less than 90 days — net mean?
- Net cash change from short-term borrowing and repayment.